

**HAEMONETICS CORPORATION**  
**TECHNOLOGY COMMITTEE CHARTER**

This Charter governs the operations of the Technology Committee (the “**Committee**”) of the Board of Directors (the “**Board**” or the “**Board of Directors**”) of Haemonetics Corporation (the “**Company**”).

**Purpose**

The Committee is appointed to assist the Board of Directors in overseeing and providing counsel on scientific, innovation and technology activities at the Company.

**Committee Membership**

The Committee shall be comprised of three or more directors. The members of the Committee shall be appointed annually by the Board of Directors upon the recommendation of the Governance and Compliance Committee. The Board of Directors shall designate a member of the Committee as the chair. Committee members may be replaced by the Board of Directors.

The members of the Committee shall meet the independence requirements set forth in the Company’s Principles of Corporate Governance and of the New York Stock Exchange as they exist from time to time.

**Meetings**

The Committee shall meet at least two times per year in person or by telephone or video conference or similar means of remote communication. The Committee shall meet at such times as determined by its chair or as requested by any two of its members. A majority of the members of the Committee shall constitute a quorum for purposes of holding a meeting. The Committee may act by an affirmative vote of a majority of members present at any meeting. In lieu of a meeting, the Committee may act by unanimous written consent.

**Duties and Responsibilities**

1. The Committee shall periodically review and make recommendations to the Board of Directors regarding:
  - the alignment of the Company’s innovation and new product development agenda with its strategy and growth objectives;
  - emerging trends in medical practice, science and technology (including potentially disruptive technology) and industry conditions that could significantly impact the Company and its products; and
  - the Company’s intellectual property portfolio and related strategy.

2. The Committee shall review the overall direction, effectiveness, competitiveness and timing of the Company's research and development programs and pipelines, including periodic review of the Company's:

- significant innovation and new product developments and lifecycle management activities in light of critical developments in its core markets;
- capabilities regarding quality assurance, regulatory affairs and clinical and medical affairs in support of the Company's new product development and lifecycle management;
- capabilities regarding the transfer of technology from research and development to manufacturing;
- resources and budget to support innovation and new product development and lifecycle management activities; and
- capability building efforts in light of its research and development and acquisition plans and investments.

3. As requested by the Board of Directors, the Committee shall evaluate the technology aspects of potential acquisitions.

4. The Committee shall periodically evaluate the technology aspects of new and existing products and services as they relate to quality, safety and cybersecurity.

5. The Committee shall receive periodic reports on the meetings and activities of targeted medical advisory boards the Company may conduct from time to time and may make recommendations regarding the agendas of such medical advisory boards.

6. The Committee may perform such other functions as may be requested by the Board of Directors from time to time.

7. The Committee may form and delegate authority to subcommittees when appropriate.

8. The Committee shall make regular reports to the Board of Directors.

9. The Committee shall have the authority to obtain advice and assistance from internal or external legal, accounting or other advisers. The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to any advisors employed by the Committee and for payment of ordinary administrative expenses of the Committee that are necessary or appropriate in carrying out its responsibilities.

10. The Committee shall review and reassess the adequacy of this Charter annually and recommend any proposed changes to the Board for approval.

11. The Committee shall annually review its own performance and report the results of its self-assessment to the full Board.

ADOPTED: January 24, 2019

AMENDED: October 28, 2020

AMENDED: January 23, 2025